Next Science (ASX:NXS) Other Current Assets: A$0.83 Mil (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:NXS Next Science Ltd ASX:NXS
25 GF Score
Price A$0.15
GF Value A$37.70
! 7 Warning Signs
View Full Analysis

What is Next Science Other Current Assets?

Next Science ASX:NXS 25 Other Current Assets is A$0.83 Mil as of Jun. 2025. GuruFocus rates ASX:NXS with a GF Score™ of 25/100 and a GF Value™ of A$37.70. The stock has 7 warning signs investors should review.

Next Science's other current assets for the quarter that ended in Jun. 2025 was A$0.83 Mil.

Next Science's quarterly other current assets declined from Jun. 2024 (A$0.81 Mil) to Dec. 2024 (A$0.50 Mil) but then increased from Dec. 2024 (A$0.50 Mil) to Jun. 2025 (A$0.83Mil).

Next Science's annual other current assets declined from Dec. 2022 (A$0.80 Mil) to Dec. 2023 (A$0.56 Mil) declined from Dec. 2023 (A$0.56 Mil) to Dec. 2024 (A$0.50 Mil).


Next Science Other Current Assets Related Terms


Next Science Other Current Assets Historical Data

* Premium members only.

The historical data trend for Next Science's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Next Science Other Current Assets Chart

Next Science Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Current Assets
Get a 7-Day Free Trial 0.60 0.67 0.80 0.56 0.50

Next Science Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.91 0.56 0.81 0.50 0.83
ASX:NXS
25GF Score
Next Science Ltd ASX:NXS
Other Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Next Science Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.

Frequently Asked Questions Learn more about Other Current Assets →
What does a Other Current Assets of A$0.83 Mil mean?
Next Science (ASX:NXS) has a Other Current Assets of A$0.83 Mil as of Jun. 2025. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Next Science.
Is Next Science's Other Current Assets too high?
Next Science's current Other Current Assets is A$0.83 Mil. Overall, Next Science has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Next Science's Other Current Assets compare to GCAN and PTPI?
Next Science's Other Current Assets of A$0.83 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Assets for a Drug Manufacturers company?
A good Other Current Assets depends on the Drug Manufacturers industry context. However, Other Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Assets mean?
A high Other Current Assets can signal that a stock is expensive relative to its fundamentals. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Next Science. Next Science's current Other Current Assets is A$0.83 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Next Science stock overvalued right now?
Next Science (ASX:NXS) has a current Other Current Assets of A$0.83 Mil. The stock's GF Value™ is A$37.70, compared to a current price of A$0.15 — trading 99.6% below its estimated fair value. The current Other Current Assets is A$0.83 Mil. Next Science's overall GF Score™ is 25/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Assets calculated?
Other Current Assets is calculated from a company's financial statements. For Next Science (ASX:NXS), the current Other Current Assets is A$0.83 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Next Science (ASX:NXS) Overvalued in 2026?

Based on GuruFocus' analysis, Next Science stock appears to be undervalued. The current stock price of A$0.15 is trading 99.6% below its estimated GF Value™ of A$37.70.

Key valuation signals for ASX:NXS:

  • Other Current Assets: A$0.83 Mil
  • GF Value™: A$37.70 vs. price of A$0.15 (99.6% below fair value)
  • GF Score™: 25/100 with 7 warning signs

No single metric tells the full story. See the ASX:NXS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Next Science Business Description

Address 264-278 George Street, Level 14, Australia Square, HWL Ebsworth, Sydney, NSW, AUS, 2000
Next Science Ltd is a medical technology company. It is engaged in the development and commercialization of its proprietary Xbio technology to reduce the impact of biofilm-based infections in human health. Xbio is a non-toxic technology with efficacy in eradicating both biofilm-based and free-floating bacteria. Its products include Bactisure, XEPERIENCE and BLASTX. The company derives revenue from North America, New Zealand, and Australia.
25GF Score

Get the complete analysis for ASX:NXS

Other Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.15
Price
A$37.70
GF Value